Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Current IL-17 inhibitors available or in development.
| Drug | Name | Target | Approvals | First approval |
|---|---|---|---|---|
| Bimekizumab | In phase 3 | IL-17 A, F | Not yet approved | N/A |
| Brodalumab | Siliq™/Kyntheum® | IL-17 RA | Psoriasis | 2018 |
| Ixekizumab | Taltz® | IL-17 A | Psoriasis, PsA, AS | 2017 |
| Secukinumab | Cosentyx® | IL-17 A | Psoriasis, PsA, AS | 2015 |
| Netakimab* | Efleira® | IL-17 A | Psoriasis | 2019 |
Approved in the Russian federation only.
AS, ankylosing spondylitis; IL, interleukin; PsA, psoriatic arthritis.
